We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Biogen’s Aducanumab for Alzheimer’s Fails to Convince FDA Advisory Committee
Biogen’s Aducanumab for Alzheimer’s Fails to Convince FDA Advisory Committee
Biogen and the FDA failed to convince an advisory committee in a crucial meeting Friday that the company’s potential blockbuster Alzheimer’s drug aducanumab has shown enough evidence of effectiveness.